id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-016814-tf17dpo5	Enes, Sara Rolandsson	Clinical Application of Stem/Stromal Cells in COPD	2019-08-07		.txt	text/plain	10751	521	40	Despite increasing number of preclinical studies demonstrating that systemic MSC administration can prevent or treat experimental COPD and emphysema, clinical studies have not been able to reproduce the preclinical results and to date no efficacy or significantly improved lung function or quality of life has been observed in COPD patients. performed a Phase I, prospective, open-label study (NCT01306513) where they aimed to assess the safety and feasibility of intravenously infused bone marrow-derived MSCs for ten patients with severe emphysema that had serial lung volume reduction surgeries (LVRS). Current clinical trials that aimed to evaluate the effect of MSC administration in COPD patients differ in a wide range of factors such as routes of administration, number of MSC administered, number of administrations, use of fresh MSCs or culture-expanded MSCs. Furthermore, all the investigations discussed above, were phase I-II studies that were underpowered in order to detect potential efficacy and no improved pulmonary function or respiratory quality of life was observed.	./cache/cord-016814-tf17dpo5.txt	./txt/cord-016814-tf17dpo5.txt